No Data
Third Quarter Report 2024
Hailan Pharmaceutical (688302.SH) released its performance for the first three quarters, with a net loss of 0.154 billion yuan.
Hochuen Pharmaceuticals (688302.SH) disclosed the third quarter report for 2024, achieving revenue of 11...
Haisco Pharmaceutical Co., Ltd. (688302.SH): The oral PROTAC drug HP568 tablets for the clinical trial of ER+/HER2- advanced breast cancer obtained the Drug Clinical Trial Approval Letter.
Gelonghui October 15th | Haichuang Pharmaceutical (688302.SH) announced that it has received the "Drug Clinical Trial Approval Notice" issued by the China National Medical Products Administration Drug Evaluation Center, approving the HP568 tablets for clinical trials for the treatment of late-stage breast cancer with estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2- late-stage breast cancer). According to the announcement, as of this announcement date.
Haisco Pharmaceutical (688302.SH): Yingchuang Power has cumulatively reduced its shareholding by 1%.
GeLongHui, October 14th | HaiChuang Pharmaceutical (688302.SH) announced that the company recently received a notice from YingChuang Power regarding the expiration of the shareholding reduction plan period and the results of the reduction. As of October 14, 2024, the current shareholding reduction plan period has expired. During the implementation of this shareholding reduction plan, YingChuang Power has cumulatively reduced 990,150 shares of the company's stock, accounting for 1.00% of the total share capital of the company.
Express News | Star market closing: SSE Science and Technology Innovation Board 50 Index fell by 0.48%, medical instruments and biopharmaceutical sectors declined.
Express News | Star Market Closing Report: Shares of innovative drug concept stocks in Haichuang Pharmaceutical hit the limit up, while the software sector collectively rose.
No Data
No Data